CARBON DIOXIDE, USP (carbon dioxide) by Carbon Biosciences is x-ray contrast activity [moa]. Approved for actinic keratosis. First approved in 2013.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
CARBON DIOXIDE, USP is an inhaled gas formulation approved as a radiographic contrast agent with X-ray contrast activity mechanism of action. It is indicated for the treatment of actinic keratosis. The product operates through contrast-based activity, distinguishing it mechanistically from topical and systemic competitors in the dermatology space.
Product is at peak commercial maturity with moderate competitive pressure (30), indicating stable market position but limited growth upside for expanding teams.
X-Ray Contrast Activity
Radiographic Contrast Agent
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury
Carbon Dioxide Investigation
Influence of Caffeine on Psychomotor Vigilance and Carbon Dioxide Tolerance During Graded Hypercapnia
RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients
Worked on CARBON DIOXIDE, USP at Carbon Biosciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
CARBON DIOXIDE, USP offers limited career growth due to zero linked job openings and peak-stage commercial maturity with no clinical expansion pipeline. Roles on this product are primarily focused on defending market share against established competitors rather than driving innovation or team expansion.